Dr Eliza Yankova is a Research Associate in the Tzelepis Group at the Milner Therapeutics Institute (University of Cambridge) and a visiting scientist at the Wellcome Sanger Institute. She completed her undergraduate degree in Biomedical Sciences at the University of Bradford (England), with an emphasis on microbiology. She then obtained her PhD from the University of Ulster (Northern Ireland), where she studied the role of infection with Propionibacterium acnes (the bacterium implicated in acne) in the development of prostate cancer. Following the successful defence of her thesis she joined the Kosuke Yusa’s group at the Wellcome Sanger Institute where she worked on using CRISPR/Cas9 technology to identify novel pluripotency genes. At the same time, using CRISPR/Cas9 screening, she also worked on identifying genes important for key stages of pancreatic development. The following year she joined Kostas Tzelepis’ team where she started working on RNA-modifying enzymes and their role in the development in myeloid malignancies (particular acute myeloid leukaemia (AML)), where she published her first Nature paper describing small-molecule inhibition of METTL3 as a potential therapy for AML.
Advertizing
